Jeffrey Greve

Jeffrey Greve

Company: Kyverna Therapeutics, Inc

Job title: CSO

Seminars:

Panel Discussion: Developing a More Targeted Approach to Activating Treg Cells to Enhance Efficacy of Treatment in Patients 9:30 am

Addressing the challenge of polyclonal Tregs to outline the risk of effector T cells becoming stimulated and causing damage Overcoming the challenge of polyclonal Tregs through development of engineered Treg approaches How can clinical outcomes with regulatory T cell therapies be improved?Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.